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Abstract
Importance—Converging evidence indicates that clusterin, a chaperone glycoprotein, influences
Alzheimer's disease (AD) neurodegeneration. However, the precise role of clusterin in AD
pathogenesis is still not well understood.
Objective—To elucidate the relationship between clusterin, amyloid-β (Aβ), p-tau, and rate of
brain atrophy over time among non-demented older individuals.
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Design—A longitudinal cohort of cognitively normal older participants (HC) and individuals
with mild cognitive impairment (MCI) assessed with baseline lumbar puncture and longitudinal
structural MRI.
Setting—Research centers across the United States and Canada.
Participants—We examined 241 non-demented older individuals (91 participants with a
Clinical Dementia Rating (CDR) of 0 and 150 individuals with a CDR of 0.5).
Main Outcome Measures—Using linear mixed effects models, we investigated interactions
between CSF clusterin, CSF Aβ1-42 and CSF p-tau181p on atrophy rate of the entorhinal cortex and
hippocampus.
Results—Across all participants, we found a significant interaction between CSF clusterin and
CSF Aβ1-42 on entorhinal cortex atrophy rate, but not on hippocampal atrophy rate. CSF clusterin
was associated with entorhinal cortex atrophy rate among CSF Aβ1-42 positive individuals, but not
among CSF Aβ1-42 negative individuals. In secondary analyses, we found significant interactions
between CSF Aβ1-42 and CSF clusterin and CSF Aβ1-42 and CSF p-tau181p on entorhinal cortex
atrophy rate. We found similar results in subgroup analyses within the MCI and HC cohorts.
Conclusions and Relevance—In non-demented older individuals, Aβ-associated volume loss
occurs in the presence of elevated clusterin. The effect of clusterin on Aβ-associated brain atrophy
is not confounded or explained by p-tau. These findings implicate a potentially important role for
clusterin in the earliest stages of the AD neurodegenerative process and suggest independent
effects of clusterin and p-tau on Aβ-associated volume loss.
Introduction
Converging genetic, cellular, molecular and biomarker evidence indicates that clusterin, a
chaperone glycoprotein also known as apolipoprotein J, influences Alzheimer's disease (AD)
pathogenesis. Clusterin levels are increased in AD-affected brain regions 1-3 and elevated in
the cerebrospinal fluid (CSF) of AD patients. 4 Several genome-wide association studies
have identified clusterin gene variants as AD susceptibility loci. 5 Elevated plasma clusterin
levels are associated with disease prevalence and severity of AD 6 and with increased
amyloid deposition and brain atrophy. 7 Still, experimental findings suggest that clusterin
increases both amyloid-β (Aβ) aggregation and clearance, 5 raising the question of whether
elevated clusterin levels are beneficial or harmful.
In humans, structural MRI and CSF biomarkers allow for the indirect assessment of cellular
changes underlying AD in vivo. Structural MRI provides measures of brain atrophy, which
includes loss of dendrites, synapses 8 and neurons. 9 Low CSF levels of Aβstrongly correlate
with intracranial amyloid plaques and high concentrations of CSF phospho-tau (p-tau)
correlate with tau-associated neurofibrillary tangles. 10 Here, we investigated whether
interactions between increased CSF clusterin and decreased CSF Aβ1-42 and increased CSF
clusterin and increased CSF p-tau181p are associated with increased brain atrophy over time
in non-demented older individuals at risk for developing AD. Building upon recent evidence
that Aβ-associated volume loss occurs in the presence of elevated p-tau, 11-15 we also
examined the additive effect on volume loss of an interaction between increased CSF
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clusterin and decreased CSF Aβ1-42 in the presence of an interaction between increased CSF
p-tau181p and decreased CSF Aβ1-42.
Subjects and Methods
A total of 313 non-demented older participants from the Alzheimer's Disease Neuroimaging
Initiative (ADNI) underwent longitudinal MRI imaging and CSF lumbar puncture. Of these,
we restricted analyses to 91 cognitively normal older adults (HC) and 150 individuals with
amnestic mild cognitive impairment (MCI) who had quality-assured baseline and at least
one follow-up MRI scan (6 months to 3.5 years, 4% with six month follow-up, 8% with
twelve month follow-up, 11% with eighteen month follow-up, 42% with twenty-four month
follow-up, and 35% with thirty-six month follow-up) (Table 1)(for additional details see
Supplemental Material).
We examined baseline CSF clusterin levels derived from a multiplex-based immunoassay
panel based on Luminex immunoassay technology developed by Rules Based Medicine
(MyriadRBM). 16 In brief, the ADNI Biomarker Core assessed CSF samples (159 analytes
measured by the MyriadRBM) from a total of 327 individuals. These baseline CSF samples
had matching aliquots from one year allowing evaluation of test-retest to determine analyte
precision. For each analyte, a multi-step quality control procedure was implemented which
included evaluation of CSF signal characteristics (high, medium and low), assessment for
normality of distribution (not-normal values were transformed) and need for imputation
(data with missing values and high/low values) (for additional details on CSF quality control
procedures, please see reference 16). We used the quality-controlled values for CSF
clusterin in all analyses. Using previously proposed CSF cutoffs 17 we examined baseline
CSF Aβ1-42 and p-tau181p levels and classified participants based on low (<192 pg/ml,
“positive”) and high (>192 pg/ml, “negative”) Aβ1-42 levels, and high (>23 pg/ml,
“positive”) and low (<23 pg/ml, “negative”) p-tau181p levels. As previously described, 17
CSF Aβ1-42 and p-tau181p were measured using the multiplex xMAP Luminex platform
(Luminex Corp, Austin TX) with Innogenetics (INNOBIA AlzBio3, Ghent, Belgium)
immunoassay kit–based reagents.
We analyzed 977 T1-weighted MRI scans using a modified version of the FreeSurfer
software package (http://surfer.nmr.mgh.harvard.edu). These analysis procedures have been
applied, validated, and described in detail in a number of publications. 18 The MRI scans
were reviewed for quality, automatically corrected for spatial distortion due to gradient
nonlinearity, registered and averaged to improve the signal to noise ratio. The cortical
surface was automatically reconstructed and gray matter thickness measurements were
obtained at each point across the cortical mantle. Here, we primarily focused on the
entorhinal cortex and hippocampus, two medial temporal lobe regions that are affected in
the earliest stages of AD 19 (Figure 1). We additionally evaluated the amygdala and middle
temporal gyrus, two temporal lobe regions that are also affected in AD. 19 The entorhinal
cortex and middle temporal gyrus were delineated using an automated, surface-based
cortical parcellation atlas. 20 The hippocampus and amygdala were identified using an
automated, subcortical segmentation atlas. 21 For the analysis of the longitudinal gray matter
volume change, we used Quarc (quantitative anatomical regional change), a recently
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developed method from our laboratory. 22,23 Briefly, each participant's follow-up image was
affine-aligned to the baseline scan and locally intensity-normalized. Using nonlinear
registration, a deformation field was then calculated to locally register the images with high
fidelity for both large- and small-scale structures, including those with low boundary
contrast. From the deformation field, a volume-change field (atrophy) can directly be
calculated. Using the baseline subcortical and cortical ROIs, the volume-chang field can be
sampled at points across the cortical surface or averaged over subcortical regions to give the
percent volume change for those ROIs (Figure 1).
We asked whether statistical interactions between CSF clusterin and CSF Aβ1-42 and
between CSF clusterin and CSF p-tau181p are associated with brain atrophy over time
(Figure 2). Using a linear mixed effects model, we concurrently examined the main and
interactive effects of CSF clusterin, CSF Aβ1-42, and CSF p-tau181p on atrophy rate of the
temporal lobe regions (entorhinal cortex, hippocampus, amygdala, and middle temporal
gyrus), co-varying for age, sex, carrier status for the ε4 allele of apolipoprotein E (APOE
ε4), group status (MCI vs. HC), and disease severity (assessed using CDR-Sum of Boxes, a
composite measure that characterizes six domains of cognitive and functional
performance 24). Of note, the main effects of all variables (the three CSF analytes and all
covariates) were also included in these analyses. For brevity, we focus below on the effects
of interest. Specifically:
(Equation
1)
where Δv = entorhinal cortex or hippocampal atrophy (millimeters3) and Δt = change in time
from baseline MRI scan (years). Intercept and slope (β0 andβ1) were entered as mixed
effects.
Prior findings from our laboratory indicate that Aβ-associated neurodegeneration occurs in
the presence of elevated p-tau. 11-13 To test whether the effect of clusterin on Aβ-associated
neurodegeneration is independent from the effect of p-tau on Aβ-associated
neurodegeneration, we performed secondary analyses and fit the following linear mixed
effects model:
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(Equation
2)
where Δv = entorhinal cortex or hippocampal atrophy (millimeters3) and Δt = change in time
from baseline MRI scan (years). Intercept and slope (β0 andβ1) were entered as mixed
effects. We co-varied for age, sex, APOE ε4 carrier status, group status (MCI vs. HC), and
CDR-Sum of Boxes. The main effects of all variables (the three CSF analytes and all
covariates) were also included in these analyses.
To evaluate whether the above described effects of interest between CSF clusterin, CSF
Aβ1-42 status, and CSF p-tau181p status were different between the MCI and HC cohorts, we
performed additional analyses fitting group status (MCI vs HC) as an interaction with
change in time from baseline MRI scan (Δt or time) and the main interactive effects. The
main effects of all variables (the three CSF analytes and all covariates) were also included in
these analyses.
Results
Results from the primary analyses revealed a significant three-way interaction between CSF
clusterin, CSF Aβ1-42 status and time (β5 = -0.032, standard error (SE) = 0.01, p = 0.01)
indicating that increased CSF clusterin and positive CSF Aβ1-42 status were associated with
an elevated entorhinal cortex atrophy rate. In contrast, the interaction between CSF clusterin,
CSF p-tau181p status and time was not significant (β6 = 0.01, SE = 0.01, p = 0.54). With both
of these three-way interaction terms in the model, only the effect of CSF Aβ1-42 status by
time was significantly associated with entorhinal atrophy cortex rate (β3 = 0.04, SE = 0.02, p
= 0.02); the effect of time by CSF clusterin and CSF p-tau181p status was not associated with
entorhinal cortex atrophy rate. None of the main effects of CSF clusterin, CSF Aβ1-42 status
and CSF p-tau181p status were significant.
Follow-up analyses examining the three way interactions demonstrated that the CSF
clusterin by time interaction was significantly associated with entorhinal cortex atrophy only
among CSF Aβ1-42 positive individuals (β-coefficient = -0.20, SE = 0.007, p = 0.008) but
not among CSF Aβ1-42 negative individuals (β-coefficient = 0.007, SE = 0.008, p = 0.36)
(Figure 3a). In contrast, there was no significant CSF cluster in by time interaction on
entorhinal cortex atrophy rate either among CSF p-tau181p positive (β-coefficient = -0.01, SE
= 0.01, p = 0.28) or among CSF p-tau181p negative individuals (β-coefficient = 0.005, SE =
0.007, p = 0.49) (Figure 3b). Similar results were obtained when CSF p-tau181p and CSF
Aβ1-42 were treated as continuous rather than categorical variables (see Supplemental
Results).
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To determine whether these effects differed by group status (MCI vs HC), we performed
additional analyses fitting interactions between group status and the main effects of interest
(for additional details see Subjects and Methods). These analyses showed a significant
interaction between group status, time, CSF clusterin and CSF Aβ1-42 status on entorhinal
cortex atrophy rate (β-coefficient = -0.031, SE = 0.009, p-value = 0.001). Follow-up
subgroup analyses revealed that although both the MCI and HC cohorts demonstrated a
significant three-way interaction of time, CSF clusterin and CSF Aβ1-42 status on entorhinal
cortex atrophy rate, whereby entorhinal cortex volume loss was significantly associated with
CSF clusterin only among CSF Aβ1-42 positive individuals, the slopes of change over time
were steeper among the MCI cohort than the HC cohort (MCI: β-coefficient = -0.076, SE =
0.03, p = 0.008; HC: β-coefficient = -0.047, SE = 0.01, p = 0.001). The interaction between
group status, time, CSF clusterin and CSF p-tau181p status was not significant. Similar
results were obtained when CSF p-tau181p and CSF Aβ1-42 were treated as continuous rather
than categorical variables (see Supplemental Results).
To determine whether similar associations could be observed in other temporal lobe areas
affected later in the disease process, we repeated these analyses using atrophy rates of the
hippocampus, amygdala, and middle temporal gyrus. Results revealed no significant
interactions of CSF clusterin, CSF Aβ1-42 status, and time on atrophy rate of the
hippocampus (β-coefficient = -0.013, SE = 0.01, p = 0.33), amygdala (β-coefficient =
-0.015, SE = 0.01, p = 0.24) and middle temporal gyrus (β-coefficient = -0.009, SE = 0.01, p
= 0.39). As observed for entorhinal cortex atrophy rate, the interaction of CSF clusterin,
CSF p-tau181p status and time was not significant for atrophy rate of the hippocampus (β-
coefficient = 0.004, SE = 0.01, p = 0.74), amygdala (β-coefficient = 0.005, SE = 0.01, p =
0.74) and middle temporal gyrus (β-coefficient = 0.016, SE = 0.01, p = 0.18).
To determine whether the effect of clusterin on Aβ-associated neurodegeneration is
independent from the previously observed effect of p-tau on Aβ-associated
neurodegeneration, 11-13 we included interaction terms with CSF p-tau181p status (for
additional details see Subjects and Methods and Equation 2). These analyses on the full
cohort revealed significant interactions between CSF clusterin, CSF Aβ1-42 status, and time
(β-coefficient = -0.026, SE = 0.01, p = 0.01) and CSF p-tau181p status, CSF Aβ1-42 status
and time (β-coefficient = -0.010, SE = 0.004, p = 0.01) on entorhinal cortex atrophy
indicating independent effects of CSF clusterin and CSF p-tau181p on CSF Aβ1-42 associated
volume loss. As in the primary analyses, with the interaction terms in the model, only the
effect of CSF Aβ1-42 status by time was significant (β-coefficient = 0.04, SE = 0.01, p =
0.009); the effects of time by CSF clusterin and CSF p-tau181p status were not significant.
The main effects of CSF clusterin, CSF Aβ1-42 status or CSF p-tau181p status were not
significant.
Additional interaction analyses with group status demonstrated significant interactions
between group status, time, CSF clusterin and CSF Aβ1-42 status (β-coefficient = -0.020, SE
= 0.003, p-value = 0.01) and between group status, time, CSF p-tau181p status and CSF
Aβ1-42 status (β-coefficient = -0.008, SE = 0.003, p-value = 0.009) on entorhinal cortex
atrophy rate. Subgroup analyses showed that within the MCI cohort, interactions between
both CSF clusterin, CSF Aβ1-42 status, and time (β-coefficient = -0.047, SE = 0.02, p = 0.01)
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and CSF p-tau181p status, CSF Aβ1-42 status, and time (β-coefficient = -0.014, SE = 0.007, p
= 0.048) on entorhinal cortex atrophy were significant. Within the HC cohort, only the
interaction between CSF clusterin, CSF Aβ1-42 status, and time on entorhinal cortex atrophy
was significant (β-coefficient = -0.032, SE = 0.01, p = 0.02); the interaction between CSF p-
tau181p status, CSF Aβ1-42 status and time on entorhinal cortex atrophy was not significant
(β-coefficient = -0.005, SE = 0.004, p = 0.23).
Comment
Here, we show that in non-demented older individuals, Aβ-associated entorhinal cortex
atrophy occurs in the presence of elevated clusterin. We also found that the effect of
clusterin on Aβ-associated entorhinal cortex atrophy is not confounded or explained by p-
tau. Taken together, this implicates a potentially important role for clusterin in the earliest
stages of the Alzheimer's neurodegenerative process and suggests independent effects of
clusterin and p-tau on Aβ-associated volume loss (Figure 4).
Though a number of studies have evaluated the relationship between Aβ, tau and p-tau on
volume loss in the earliest stages of AD, 11-15 the role of clusterin in modulating this
relationship is still unknown. Our findings demonstrate that non-demented older individuals
with elevated CSF clusterin and decreased Aβ (i.e. increased intracranial Aβ deposition)
experience increased volume loss suggesting that clusterin may accelerate progression from
amyloid deposition to neurodegeneration. These results also indicate that a biomarker profile
incorporating CSF clusterin, CSF Aβ1-42 and CSF p-tau181p levels may better identify those
older individuals who are at an elevated risk of progressing to dementia than any of these
biomarkers by themselves.
These findings provide novel insights into the preclinical stage of AD. Though prior
research suggests that clusterin by itself may not represent a marker of presymptomatic
AD, 6 our work indicates that the presence of clusterin may represent a critical link between
Aβ deposition and entorhinal cortex degeneration in preclinical AD. Furthermore, in
secondary analyses among HC participants, we found a significant interaction on volume
loss only between clusterin and Aβ whereas among MCI individuals we noted concurrent
interactions of Aβ with both clusterin and p-tau suggesting that the clusterin related effects
on Aβ-associated neurodegeneration may precede tau related effects. Finally, in contrast to
p-tau-related atrophy within the later-affected hippocampus or other temporal lobe regions,
we found clusterin-associated effects only for the entorhinal cortex, a region selectively
affected in the earliest stages of AD. 19 Considered together, these findings indicate that the
interaction between clusterin and Aβmay provide an important window into the earliest
stages of the Alzheimer's neurodegenerative process.
Cellular and molecular evidence suggests that an interaction between clusterin and Aβ
potentiates neurotoxicity. Though prior experimental 25 and plasma-based human studies
suggest that elevated clusterin levels may represent a non-etiopathological, neuroprotective
response, 6,26 the molecular mechanism by which clusterin effects AD pathology is still not
well understood. Recent experimental evidence indicates that knockdown of clusterin
protects against Aβ-induced apoptosis whereas neuronal treatment with Aβ increases
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intracellular clusterin (and decreases extracellular clusterin), resulting in wnt/Dickkopf-1-
induced neurotoxicity. 27 Importantly, this clusterin-dependent, wnt/Dickkopf-1-induced
apoptotic effect is specific to Aβ and is not observed with tau or other cytotoxic agents. 27
As a chaperone, clusterin has also been shown to bind with Aβ, thus increasing the rate of
fibrillar amyloid deposition and neuritic dystrophy 28 and potentiating Aβ oligomeric
neurotoxicity. 29 Consistent with these experimental results, our human findings suggest that
clusterin may affect AD neurodegeneration primarily via Aβ-associated mechanisms.
A limitation of our study is its observational nature, which precludes conclusions regarding
causation. Our results cannot differentiate whether elevated clusterin causes, results from, or
is simply correlated with amyloid deposition and entorhinal cortex atrophy. Additionally,
our findings require further validation on a larger, independent population-based cohort.
From a translational perspective, though considerable efforts have focused on Aβ and tau,
comparatively little is known about other proteins influencing Alzheimer's
neurodegeneration. Our findings implicate the involvement of clusterin in the earliest stages
of AD. Using experimental models, it will be essential to better delineate the differential
mechanistic aspects of intracellular from extracellular clusterin. In humans, it would be
helpful to understand whether CSF and plasma clusterin levels correspond to experimentally
derived intracellular or extracellular clusterin. It will also be important to determine whether
interactions between clusterin and other factors modulate Aβ-associated neurotoxicity.
Along with our current findings, the results from these studies could provide valuable
insights into whether modifying clusterin levels or blocking clusterin/Aβ interactions are
likely to represent viable therapeutic approaches for individuals in the earliest phases of the
disease process.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
T1-weighted MRI images in the coronal dimension and a medial semi-inflated gray matter
cortical surface depicting the entorhinal cortex and hippocampus (a and b) and 1-year
volume change fields (c and d) for an MCI participant at the median for entorhinal cortex
and hippocampal volume loss (annualized percent change) who was Aβ positive, p-tau
positive and demonstrated elevated clusterin levels. (a) Automated segmentation of the
baseline, structural MRI with subcortical structures (including the hippocampus) depicted in
various colors. (b) The red overlay shows the gray matter/CSF boundary, the white overlay
depicts the gray/white matter boundary and the distance between these surfaces represents
the cortical thickness. Here, we were primarily interested in evaluating longitudinal thinning
of the entorhinal cortex. (c) Heat map representation of the voxel-wise estimates of
volumetric change at 1-year. Note that volumetric change is most pronounced in the medial
temporal lobe. (d) Semi-inflated gray matter cortical surface (medial hemisphere) with a
heat map representation of cortical volumetric change at 1-year. Note that volumetric change
is most pronounced in the medial temporal and temporopolar cortices. H= hippocampus, A
= amygdala, TH = temporal horn lateral ventricles, P = putamen, GP = globus pallidus, EC
= entorhinal cortex, RS = rhinal sulcus.
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Figure 2.
Diagrammatic representation of the primary hypotheses evaluated in the current study where
the primary outcome was longitudinal entorhinal cortex atrophy: (β1) main effect of
clusterin, (β2) main effect of Aβ1-42, (β3) main effect of p-tau,(β4 and ⊙) an interactive effect
between clusterin and Aβ1-42, and (β5 and ⊙) an interactive effect between clusterin and p-
tau.
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Figure 3.
(a) Spaghetti plots illustrating atrophy of the entorhinal cortex among all non-demented
older participants classified as Aβ1-42 positive and high clusterin (based on median value of
clusterin) (top left panel), Aβ1-42 positive, and low clusterin (top right panel), Aβ1-42
negative and high clusterin (bottom left panel), and Aβ1-42 negative and low clusterin
(bottom right panel). The red line indicates the mean atrophy rate for the four respective
groups (i.e. Aβ1-42 positive and high clusterin, Aβ1-42 positive and low clusterin, Aβ1-42
negative and high clusterin and Aβ1-42 negative and low clusterin). As illustrated in the top
panel, the slopes of the red lines between the Aβ1-42 positive and high clusterin and Aβ1-42
positive and low clusterin individuals are significantly different corresponding to the
significant interaction between CSF Aβ1-42, CSF clusterin and time (please see text for
further details).
(b) Spaghetti plots illustrating atrophy of the entorhinal cortex among all non-demented
older participants classified as p-tau positive and high clusterin (based on median value of
CSF clusterin) (top left panel), p-tau positive, and low clusterin (top right panel), p-tau
negative and high clusterin (bottom left panel), and p-tau negative and low clusterin (bottom
right panel). The red line indicates the mean atrophy rate for the four respective groups (i.e.
p-tau positive and high clusterin, p-tau positive and low clusterin, p-tau negative and high
clusterin and p-tau negative and low clusterin). As illustrated in the top panel, the slopes of
the red lines between the p-tau positive and high clusterin and p-tau positive and low
clusterin individuals are not significantly different corresponding to the non-significant
interaction between CSF p-tau, CSF clusterin, and time (please see text for further details).
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Figure 4.
Results from our linear mixed effects model demonstrating independent effects of clusterin
and p-tau on Aβ-associated volume loss in non-demented older individuals (please see text
for details). ⊙illustrates an interactive effect and the arrow demonstrates a main effect of
Aβ.
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Figure 5.
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Table 1
Demographic, clinical, and imaging data for all participants in this study. MCI = mild cognitive impairment,
HC = cognitively normal older adults, MMSE = Mini-mental status exam, CDR-SB = Clinical Dementia
Rating-Sum of Boxes score, APC = Annualized Percent Change, SE = Standard error of the mean, MRI =
magnetic resonance imaging, LP-MRI interval = time in months between baseline lumbar puncture (LP) and
baseline MRI, Years between MRI scans = time between baseline and last available MRI
HC (n = 91) MCI (n = 150)
Age, Mean (SE) 76.0 (0.6) 75.1 (0.7)
Female, % 51 33
Education Years, Mean (SE) 15.6 (0.3) 16.1 (0.2)
MMSE, Mean (SE) 29.1 (0.1) 26.7 (0.1)
CDR-SB, Mean (SE) 0.03 (0.01) 1.5 (0.07)
APOE ε4 carriers (%) 24 54
CSF Clusterin level (μg/ml), Mean (SE) 1.39 (0.02) 1.42 (0.01)
CSF Aβ1-42 level (pg/ml), Mean (SE) 207.8 (5.6) 157.5 (4.1)
CSF p-tau181p level (pg/ml), Mean (SE) 24.7 (1.4) 36.8 (1.3)
LP-MRI interval (months), Mean (SE) 0.07 (0.007) 0.08 (0.006)
Years between MRI scans, Mean (SE) 2.37 (0.08) 2.17 (0.05)
Entorhinal cortex APC, Mean (SE) -0.84 (0.11) -2.37 (0.12)
Hippocampus APC, Mean (SE) -0.95 (0.08) -2.42 (0.13)
Amygdala APC, Mean (SE) -0.99 (0.10) -2.65 (0.15)
Middle Temporal Gyrus, Mean (SE) -0.70 (0.09) -1.97 (0.12)
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